Anthracyclines have been important and effective treatments against a number of cancers
since their discovery. However, their use in therapy has been complicated by severe side …

Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

Purpose Cardiac dysfunction is a serious adverse effect of certain cancer-directed therapies
that can interfere with the efficacy of treatment, decrease quality of life, or impact the actual …

The first classification on this topic categorized cardiomyopathies as heart muscle diseases
with dilated (DCM), hypertrophic, restrictive, arrhythmogenic right ventricular (ARVC), or …

Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer
receiving anthracyclines - de Baat, EC - 2022 | Cochrane Library Skip to Content Cookies Our …

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice …

Anthracyclines are the cornerstone of many chemotherapy regimens for a variety of cancers.
Unfortunately, their use is limited by a cumulative dose-dependent cardiotoxicity. Despite …

The task of developing CPG documents covers not only integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …

The anthracycline doxorubicin (DOX) is widely used in chemotherapy due to its efficacy in
fighting a wide range of cancers such as carcinomas, sarcomas and hematological cancers …

Background We conducted a systematic review and meta-analysis to clarify the risk of early
and late cardiotoxicity of anthracycline agents in patients treated for breast or ovarian …